Across the pond...Nasdaq: KZIA, page-176

Hi harvett, previously I was thinking the same as you, but needle changed my mind a few weeks ago.
IMO Interim Data from phase 2 BCBM study (provisional) refers to the Dana Farber - Breast Cancer Brain Mets (combination with Herceptin®) Phase II NCT03765983 study.
According to management's milestone schedule the Dana Farber data will be released at the same time as the ESMO (19 September 2020) Virtual Conference.
Yes, Dr Priscilla Brastianos 30 min invited address will cover her expertise in "Genetic Evolution of Brain Metastases: Implications for Precision Medicine". Many of her previous lectures have featured Paxalisib (GDC-0084) in her research presentations, I agree that Paxalisib will be mentioned in the US this Friday.

The blockbuster provisional data for NCI-funded phase 2 Alliance study in brain mets is likely early next year.



Regards.